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Hematopoietic stem cells recipients remain susceptible to opportunistic viral infections including herpes simplex virus type-1
(HSV-1). The purpose of this investigation was to analyze susceptibility of human mesenchymal stem cells (hMSCs) to HSV-1
infection and identify the major entry receptor. Productive virus infection in hMSCs was conﬁrmed by replication and plaque
formation assays using a syncytial HSV-1 KOS (804) virus. To examine the signiﬁcance of entry receptors, RT-PCR and antibody-
blocking assays were performed. RT-PCR data showed the expression of gD receptors: nectin-1, 3-O sulfotransferase-3 (3-OST-3),
and HVEM. Antibody-blocking assay together with heparinase treatment suggested an important role for HS and 3-O-sulfated
heparan sulfate (3-OS HS), but not nectin-1 or HVEM, in mediating HSV-1 entry and spread in hMSCs. Taken together, our
results provide strong evidence demonstrating that HSV-1 is capable of infecting hMSCs and HS and 3-OSH Ss e r v ea si t se n t r y
receptors during this process.
1.Introduction
Herpes simplex virus type-1 (HSV-1) is a ubiquitous
pathogen associated with facial cold sores [1, 2], but
severe complications especially in neonates and immuno-
compromised patients may result in corneal blindness,
retinitis, and encephalitis [3, 4]. The virus can also cause
severe opportunistic infections in the patients follow-
ing allogeneic stem cell transplant [5–8]. Such infections
could be donor derived or due to the reactivation of
an endogenous latent virus [9]. In addition, the drug-
resistant HSV-1 is also an emerging concern to promote
viral infections after allogeneic stem cell transplantation
[10]. It has been proposed that human mesenchymal
stem cells (hMSCs) may be susceptible to infection if
infused in patients with HSV-1 viremia and may com-
promise the host’s defense against infectious agents [7,
11].
HSV-1 infects host cells through initial attachment to
cell surface heparan sulfate (HS) followed by fusion of the
virion envelope with the plasma membrane of the host cells
[12, 13]. The current model suggests that entry of virus
requires four HSV glycoproteins (gB, gD, gH, and gL) [14–
19] and at least one cellular receptor for glycoprotein D (gD)
[20–22]. The receptors for HSV-1 gD include a member of
the TNF-receptor family named HVEM [23, 24], a member
of the immunoglobulin superfamily commonly known as
nectin-1 [25, 26]a n d3 - O sulfated heparan sulfate (3-OS
HS) [27]. The later form of HS is enzymatically modiﬁed
by multiple D-glucosaminyl 3-O-sulfotransferase (3OST)2 Journal of Biomedicine and Biotechnology
isoforms. Among the known 3-OS T si s o f o r m sa l lm e d i a t e
HSV-1 entry [27–31] and cell-to-cell fusion [22, 32]e x c e p t
3-OST-1 isoform.
Although HSV-1 infections lead to signiﬁcant morbidity
and mortality in transplant recipient [6, 10, 11], the sus-
ceptibility of human mesenchymal stems cells (hMSCs) to
HSV-1 entry and key entry mediator that allows HSV-1 in-
fection is poorly understood. In this study, we investigated
the HSV-1 infection of hMSCs and the role of HSV-1 entry
receptors in this process. The ﬁnding that HSV-1 can induce
cytopathiceﬀectandproductivelyreplicateinhMSCsinhigh
titer provides new information on the susceptible nature
of target cell population present within the host. We also
demonstrated that HS and modiﬁed form of HS (3-O-
sulfated heparan sulfate; 3-OS HS) is a major determinant
of HSV-1 entry and spread into hMSCs.
2.MaterialsandMethods
2.1. Cell Culture and Viruses. Wild-type Chinese hamster
ovarian-K1 (CHOK1) cells were grown in Ham’s F-12
medium (Gibco/BRL, Carlsbad, Calif, USA) supplemented
with 10% fetal bovine serum (FBS, Invitrogen), and peni-
cillin and streptomycin (Gibco/BRL). HeLa cells were grown
inDMEMmediasupplementedwith10%fetalbovineserum
(Invitrogen), and penicillin and streptomycin (Gibco/BRL).
African green monkey kidney (Vero cells) were grown as
previously described [33]. Human mesenchymal stem cells
(hMSCs)werepurchasedfromFisherScientiﬁc(SV3010201)
grown in Hyclone Advance STEM expansion media (Fisher
Scientiﬁc, SH30875KT). Passage 4 hMSCs were used in all
experiments described.
2.2. Plasmids. The HSV-1 (KOS) glycoprotein expressing
plasmids used were pPEP98 (gB), pPEP99 (gD), pPEP100
(gH), and pPEP101 (gL) [18]. Other plasmids used in this
study include pCalifGT7 (T7 RNA polymerase) and pT7-
EMCLuc (luciferase gene).
2.3. HSV-1 Entry Assay. Viral entry assays were based on
quantitation of β-galactosidase expressed from the viral
genome[27].Cells(hMSCs,HeLa)wereplatedat2 ×104 per
well in 96-well plates at least 16h prior to infection. After 6-
h postinfection, β-galactosidase assays were performed using
a soluble substrate o-nitrophenyl-β-D-galactopyranoside
(ONPG at 3.0mg/mL) assay. The enzymatic activity was
measured at 410nm using a microplate reader (BioTek
Instruments Inc. EL×808 absorbance microplate reader,
Vt, USA). Viral entry was further conﬁrmed by 5-bromo-
4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) staining.
The hMSCs were grown in Lab-Tek chamber slides. After
6hr of infection with the reporter virus, the cells were
washed with PBS and ﬁxed with 2% formaldehyde and 0.2%
glutaradehyde at room temperature for 15min. The cells
were then washed with PBS and permeabilized with 2mM
MgCl2, 0.01% deoxycholate and 0.02% nonidet NP-40 for
15min. After rinsing with PBS, 1.5mL of 1.0mg/mL X-gal
in ferricyanide buﬀer was added to each well, and the blue
color developed in the cells was examined. Microscopy was
performed using 40x objective of the inverted microscope
(Olympus IX50).
2.4. Fluorescent Microscopy of Viral Entry. Cultured mono-
layers of hMSCs were grown overnight in media containing
10% FBS on chamber slides (Lab-Tek). The cells were
either mock infected or infected with green ﬂuorescent
protein (GFP)-tagged HSV-1 (VP26-GFP) at 50pfu/cell in
serum-free media OptiMEM (Invitrogen). The GFP was
fused with the HSV-1 UL35 open reading frame (ORF)
which encodes a 12-kDa capsid protein designated VP26
[34]. VP26 is located on the outer surface of the capsid,
speciﬁcally on the tips of the hexons that constitute the
capsid shell. At 90min post-infection, cells were ﬁxed and
stained with 10nm rhodamine-conjugated phalloidin for
F-actin. Images of immunoﬂuorescent labeled cells were
acquired using a Olympus IX50 inverted ﬂuorescence micro-
scope.
2.5. Eﬀect of Actin Depolymerizing Agents on HSV-1 Entry
in hMSCs. In order to demonstrate the signiﬁcance of actin
cytoskeleton network during HSV-1 entry into hMSCs, the
eﬀects of actin depolymerizing agents on entry of HSV
into hMSCs were examined. Monolayer cultures of hMSCs
(approximately 106 cells) cultured in a 96-well plate were
pretreated with the indicated concentrations of agents for
1hr at room temperature with cytochalasin D (Cyto D)
and latrunculin B (Lat B) (Sigma) or mock-treated as a
control. Cells were infected with the lacZ+ HSV-1 KOS
(gL86) at 50PFU/cell for 6 h at 37◦C. ONPG entry assay was
performed to estimate the enzymatic activity at 410nm by
spectrophotometer.
2.6. Kinetics of Viral Plaque Assay. Conﬂuent layers of
hMSCs (approximately 106) in six-well dishes were infected
with HSV-1 (804) strain at 0.01PFU/cell or mock infected
for 2hrs at 37◦C. After removal of inoculum, monolayers
were overlaid with DMEM containing 2.5% heat inactivated
calf serum and incubated at 37◦C. At diﬀerent time points:
0, 12, 24, and 36hr, the cells were ﬁxed by using ﬁxative
buﬀer at room temperature for 20 min, followed by Giemsa
staining for 45min. The cells were again washed ﬁve times in
PBS, and the numbers of plaques were counted. The images
were taken by using an Olympus IX50 inverted ﬂuorescence
microscope. Virus replication was further examined by
quantitative plaque assay. A monolayer of cultured hMSCs
(approximately 4 × 106 cells per 25-mL ﬂask) was infected
(MOI, 0.01) with HSV-1(KOS) or mock infected with PBS
alone for 2h at 37◦C. Vero cells mock infected of infected
with the HSV-1 KOS under similar conditions were used
as negative and positive controls, respectively. After removal
of the inoculum, monolayers were overlaid with DMEM
containing 2.5% heat-inactivated calf serum and incubated
at 37◦C until the time of harvest (12 to 48h). Infectious
virus titers were determined on Vero cells cultured inJournal of Biomedicine and Biotechnology 3
triplicate by using an overlay of medium containing methyl-
cellulose. In order to block secondary plaque formation,
human immunoglobulin G (IgG; Sigma) was added to the
inoculum. The cells were washed with PBS buﬀer, ﬁxed
in alcohol, and stained with Giemsa stain. Infectivity was
recorded as the number of PFU. Virus attachment was
determined by using Olympus IX50 inverted ﬂuorescence
microscope.
2.7. HSV-1 gD Interference Assay. Cultured hMSCs were
transfected with Lipofectamine 2000 (Invitrogen) with an
HSV-1 gD expression plasmid (pPEP99) [18]o rac o n t r o l
plasmid (pCDNA3) in six-well dishes (1.0μg of plasmid
DNA total per well). The interference assay was performed
as described previously [35].
2.8. Detection of gD Receptors by Reverse Transcription (RT)-
PCR Analysis. Total RNA was isolated from cultured hMSCs
using a QIAGEN RNeasy kit with DNAase in column treat-
ment(QIAGENCorp.,Valencia,Calif,USA).SUPERSCRIPT
II reverse transcriptase (Invitrogen Corp.) was used for
RT to generate cDNAs. PCR ampliﬁcation of cDNAs was
done with primers 5 -GGAGACAATACCCTCATTCA-3 
and 5 -TATTTACATCCTCCCACAGC-3  for HVEM, and
primers 5 -TCCTTCACCGATGGCACTATCC-3  and 5 -
TCAACACCAGCAGGATGCTC-3  for nectin-1. The 3-
OST-3 sequences were ampliﬁed with primers 5 -CAGGCC-
ATCATCATCGG-3  and 5 -CCGGTCATCTGGTAGAA-3 .
PCR was performed using ThermoStart DNA polymerase
(Fisher cat no. AB0908) under the following conditions:
95◦C3 0   ,5 2 ◦C3 0   ,7 2 ◦C3 0   , and 32 cycles for HVEM;
95◦C1  ,6 2 ◦C1  ,7 2 ◦C2  , and 35 cycles for Nectin-1; 95◦C
1 ,5 5 ◦C1  ,7 2 ◦C2  ,a n d3 2c y c l e sf o r3 - OST. The expected
sizes of the PCR products were 582 bps for HVEM, 738bps
for nectin-1, and 736bps for 3-OST-3. The products were
separated by electrophoresis on an agarose gel soaked in gel
green solution and imaged using Bio-Rad Molecular Imager
G e lD o cX R +s y s t e m .
2.9. Antibody Blocking Assay. Antibody blocking assay was
performed as previously described [36]. hMSCs plated in
96-well plate were preincubated at room temperature with
twofold dilutions of Anti-HVEM, anti-nectin-1 antibody
(PRR1), and a control antibody (α-TGFbR II) for 90 min.
Cells were then challenged with identical doses of HSV-1
(gL86) at 5 × 105 pfu per well at 37◦C. After 6 hours, the cells
werewashedtwicewithPBSandtreatedfor1minwith0.1M
citrate buﬀer (pH 3.0). The substrate, ImmunoPure ONPG
was prepared in PBS buﬀer with nonionic detergent, and β-
galactosidase activity was read at 410nm. The experiment
was repeated three times with similar results.
2.10. Heparinase Treatment. Cultured hMSCs plated on 96-
well plates were washed with Mg2+-a n dC a 2+-free PBS and
incubated at room temperature for 90 min with heparinase
I( 1 . 5Um L −1; Sigma) or PBS alone and incubated at room
temperature. The cells were then washed with PBS and used
for HSV-1 entry [33].
2.10.1. Surface Immunoﬂuorescence Assay. To detect the
binding of HSV-1 to the surface of hMSCs, cultured mono-
layers of cells (approximately 106) were grown overnight on
glass bottom culture dishes (Mat Tek Corp.). The cells were
then treated with heparinases I (1.5UmL−1) or with PBS
buﬀer for 45min, exposed to GFP-tagged HSV-1 K26GFP
for 30min at 4◦C, and ﬁxed with acetone. The cells were
then stained with phalloidin (F-actin) and mounted on glass
slides before examination under an Olympus IX50 inverted
ﬂuorescence microscope.
2.10.2. Glycoprotein D (gD)-Fc Binding Assay. Cultured
hMSCs were plated overnight into 96-well dishes (approx-
imately 4 × 104 cells/well). They were treated with hepari-
nases I or with PBS buﬀer as described above for 2h. This
was followed by incubation with gD-Fc (1μg/mL) for 1h
andﬁxationatroomtemperaturewith2%formaldehydeand
0.02% glutaraldehyde for 15min. The cells were washed with
PBScontaining3%BSA(Sigma)andthenincubatedatroom
temperature sequentially with a biotinylated secondary anti-
body against rabbit IgG (Sigma) at a 1:500 dilution in PBS-
3% BSA for 45min and AMDEX streptavidin-conjugated
horseradish peroxidase (Amersham) at a 1:20,000 dilution
for 30min. Following washing in PBS, the cells were incu-
bated with 50μL3 , 3  ,5,5 -tetramethylbenzidine (Sigma) in
50mM phosphate-citrate buﬀer. Products were quantitated
by use of a microplate reader (BioTek Instruments Inc.
EL×808 absorbance microplate reader, Vt, USA) to measure
optical density at 650nm (OD650).
2.10.3.HSV-1Glycoprotein-InducedCellFusionAssay. Inthis
experiment, the CHO-K1 cells designated eﬀector cells were
cotransfected with plasmids expressing four HSV-1(KOS)
glycoproteins: pPEP98 (gB), pPEP99 (gD), pPEP100 (gH),
and pPEP101 (gL), along with plasmid pT7EMCLuc, which
expresses the ﬁreﬂy luciferase gene under the control of the
T7 promoter [22]. Cultured hMSCs considered target cells
were cotransfected with pCalifGT7, which expresses T7 RNA
polymerase with the chicken actin promoter and the CMV
enhancer [18]. Eﬀector cells expressing pT7EMCLuc and
pCDNA3 (devoid of any glycoproteins) and target hMSCs
transfected with T7 RNA polymerase alone were used as
negative controls. In either case, the total amount of DNA
used for transfection was kept constant. After 16h, target
and eﬀector cells were mixed in a 1:1 ratio and then replated
in 24-well dishes. Activation of the reporter luciferase gene,
as a measurement of cell fusion, was examined by reporter
lysis assay (Promega) at 24h postmixing by using a Sirius
luminometer (Berthold detection systems). Cell fusion was
also visualized for multinucleated giant cells or polykary-
ocytes by microscopy following Giemsa (Fluka) staining at
24h postmixing. Photographs of representative cells were
imaged using an Olympus IX50 inverted microscope.
3. Results
3.1. Human Mesenchymal Stem Cells (hMSCs) Are Susceptible
to HSV-1 Entry. To determine HSV-1 entry, conﬂuent
monolayers of cultured hMSCs were infected with serial4 Journal of Biomedicine and Biotechnology
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Figure 1: Herpes simplex virus type-1 (HSV-1) entry into cultured human mesenchymal stem cells (hMSCs). (a) Dosage response analysis
of HSV-1 entry into hMSCs. Recombinant HSV-1(KOS) gL86 enters hMSCs and naturally susceptible HeLa cells but not wild-type CHO-K1
cells in a dosage-dependent manner. Data represent the mean ± the standard deviation of results from triplicate wells in a representative
experiment. (b) β-galactosidase staining of HSV-1 entry. Cultured hMSCs that were exposed to HSV-1(KOS) gL86 (panel (B)) were 100%
stained blue, indicating 100% viral infection, whereas uninfected cells did not show any staining. (c) Fluorescence imaging of HSV-1 entry.
ConﬂuentmonolayercultureofhMSCsweremockinfected(panel(A))orinfectedwithGFP-taggedHSV-1(K26-GFP)at50PFU/cell(panel
(B))andstainedwithTRITC-conjugatedphalloidin(redcolor),whichbindstoF-actin.HSV-1infectedcellsshowedbothgreenﬂuorescence
from HSV-1 capsid and red ﬂuorescence from F-actin expression (green and red overlapping areas appear yellow), whereas mock-treated
cells only showed red ﬂuorescence. The images were taken on ﬂuorescent microscope at 20x magniﬁcation.
dilutions of recombinant HSV-1(KOS) gL86 [27], which
expresses β-galactosidase upon entry into cells. HeLa cells
that are naturally susceptible to HSV-1 entry were used as
a positive control. Entry of HSV-1 was measured after 6h
of viral infection. As shown in Figure 1(a), similar to HeLa
cells, HSV-1 entered hMSCs in a dose-dependent manner.
By contrast, CHO-K1 cells without any receptor remained
resistant to HSV-1 entry. Further conﬁrmation of HSV-1
entry was established using an X-gal assay. No β-gal activity
w a so b s e r v e di nm o c ki n f e c t e dh M S C s( Figure 1(b), panel
A), while a dosage of virus suﬃcient to infect 100% of
hMSCs at 10PFU/cell (Figure 1(b), panel (B)) also led to a
nearly complete infection of hMSCs. In order to obtain more
direct and visual evidence of HSV-1 entry, GFP-tagged HSV-
1(K26GFP) [34] was used to infect cultured hMSCs, and
ﬂuorescence microscopy was used to visualize the virions
inside the hMSCs stained with rhodamine phalloidin, which
speciﬁcally labels F-actin (Figure 1(c), panel (B)). The GFP
colocalization with F-actin was seen all over the cell
(Figure 1(c), panel (B)). This result correlated with the
observed susceptibility of hMSCs to HSV-1 entry during
X-gal assay.
3.2. Eﬀect of Cytoskeleton Rearrangements in hMSCs during
HSV-1 Infection. Our previous ﬁndings have shown that
HSV-1 entry into natural target cells leads to change inJournal of Biomedicine and Biotechnology 5
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Figure 2: HSV-1 entry into hMSCs is cytoskeleton dependent. (a) An infected cell showing the virus particles (green). Cells were infected
withHSV-1(K26GFP)at50PFU/cellandimaged45minpostinfection.(b)VirusparticlescolocalizewithF-actininﬁlopodia-likestructures
(boxed area). F-actin was stained by rhodamine phalloidin (red). Areas where virus particle (green) and F-actin overlap appear yellow. (c)
HSV-1(KOS) gL86 entry into hMSCs (50PFU/cell) was inhibited by actin depolymerizing agent Latrunculin B (Lat B) in a dose-dependent
manner. (d) HSV-1(KOS) gL86 entry into hMSCs (50PFU/cell) was inhibited by actin depolymerizing agent Cytochalisin D (Cyto D) in a
dose-dependent manner. The mock-treated hMSCs were used as a control. Viral entry was quantitated 6h after infection at 410nm using a
spectrophotometer ∗P<. 05, ∗∗P<. 01.
actin cytoskeleton [36–38]. We therefore decided to examine
whether cytoskeleton changes played any signiﬁcant role in
HSV-1 entry into hMSCs. To address this issue, ﬂuorescent
microscopy of hMSCs exposed to GFP-tagged HSV-1 virions
at 30min postinfection was performed. Quite noticeably,
some GFP-tagged virus particles were found to attach at
ﬁlopodia-like structures in rhodamine-phalloidin stained
hMSCs (Figures 2(a) and 2(b)). In order to demonstrate the
signiﬁcance of actin network and ﬁlopodia during HSV-1
entry into hMSCs, we used the actin inhibitors latrunculin
B (Lat B) or cytochalasin D (Cyto D). Both agents prevent
cytoskeleton changes by blocking actin polymerization [39,
40]. As shown in Figures 2(c) and 2(d), pretreatment of
hMSCs with Lat B and Cyto D resulted in signiﬁcant
inhibition of HSV-1 entry, suggesting that cytoskeleton
modiﬁcation may be needed during the initial phase of HSV-
1 infection.
3.3. HSV-1 Replicates in Cultured hMSCs. Because HSV-
1 was able to enter cultured hMSCs, we next evaluated
whether this entry led to a productive virus replication.
Initially, microscopy was used to obtain visual evidence
of HSV-1 replication. Syncytial plaque forming HSV-1
(KOS) 804 virus [41] was used for infecting cultured
hMSCs, and the virus was allowed to replicate. Cells
were ﬁxed at diﬀerent time points and Giemsa stained.
The cytopathic eﬀect in the form of plaque formation
increased signiﬁcantly overtime in virus-infected hMSCs6 Journal of Biomedicine and Biotechnology
100μm 100μm
100μm 100μm
(A) (B)
(C) (D)
(a)
∗
∗
48 36 12
Time (hr)
0
10
20
30
40
50
N
u
m
b
e
r
o
f
p
l
a
q
u
e
s
(b)
hMSC
Vero
CHO-K1
40 30 20 10 0
Time (hrs)
0
10
20
30
40
×105
T
i
t
e
r
(
P
F
U
/
m
L
)
(c)
Figure 3: HSV-1 replicates in infected hMSCs. (a) Visualization and quantiﬁcation of HSV-1 replication in cultured hMSCs. Conﬂuent
monolayers of hMSCs (5 × 106) were infected with HSV-1 KOS (804) virus at 0.01PFU/cell were ﬁxed and Giemsa stained at 0 hr (panel
(A)) 12hr (panel (B)) 24hr (panel (C)) and 48hr (panel (D)) postinfection. The numbers of plaques were visualized. (b) The number of
plaquesformedpostinfectionincreasedinatime-dependentmanner.Errorbarsrepresentstandarddeviations.(
∗P <. 05),onewayANOVA.
(c) Infectious yields of HSV-1 during viral infection were quantiﬁed. Conﬂuent monolayers of Vero and hMSCs were infected with HSV-1 at
0.01PFU per cell for 90min at 37◦C. Inoculums were harvested from both the cells at 10–40h postinfection. The infectious virus-titer (PFU
per milliliter) determined in triplicates in Vero cell by plaque assay indicates that the viral titer in cultured hMSCs increased overtime. Data
represent the mean ± the standard deviation of results in triplicate wells in a representative experiment.
as seen in Figures 3(a) and 3(b). Furthermore, to assess
viral replication, the infectious yields of virus were deter-
mined by plaque assays with Vero cells. As shown in
Figure 3(c), inoculum harvested from infected hMSCs pro-
duced a larger number of plaques overtime. In con-
trast, CHO-K1 cells infected with identical doses of the
same virus failed to produce infectious virions. These
results, together with those of the entry assay, show that
entry of HSV-1 into cultured hMSCs leads to productive
infection.
3.4. Expression of HSV-1 gD in Cultured hMSCs Renders
Resistance to HSV-1 Entry. In order to determine if the gD
receptors play a role in human hMSCs infection by HSV-1, a
gD-mediated interference assay was used [35]. This assay is
based on the principle that cells that are normally susceptible
to viral entry become resistant upon expression of viral gD
because of sequestration of gD receptors by cell-expressed
gD [35]. To carry out the assay, hMSCs were transiently
transfected with an HSV-1 gD-expressing plasmid (or an
equal amount of the empty vector, pCDNA3, as a control),Journal of Biomedicine and Biotechnology 7
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Figure 4: HSV-1 glycoprotein D (gD) receptors are important
for infection of hMSCs. Cultured hMSCs were transfected with
an HSV-1 gD expression plasmid (white dot) or with the empty
vector pCDNA3.1 (black dot) and infected with HSV-1 at two fold
dilution. Reporter enzyme activity, as a measurement of viral entry,
was measured with spectrophotometer at 410nm.
followed by infection with serial dilutions of β-galactosidase-
expressing HSV-1(KOS) gL86. As shown in Figure 4,H S V - 1
entry into gD-expressing hMSCs was approximately 2.0-fold
lower compared to the pCDNA3 control. Thus, entry into
hMSCs is likely mediated by gD receptors expressed on the
cell surface in a gD-dependent manner.
3.5. Identiﬁcation of gD Receptors Expressed in Cultured
hMSCs. Reverse transcriptase (RT)-PCR analysis was per-
formed to determine the identity of gD receptors potentially
expressed in hMSCs. Gene-speciﬁc primers for nectin-1,
3-OST-3 and HVEM were used. As shown in Figure 5(a),
products of the expected sizes for cDNAs encoding nectin-
1, 3-OST-3 and HVEM were all detected, indicating that all
three genes are normally expressed in hMSCs.
3.6. Anti-Nectin-1 and Anti-HVEM Antibody Do Not Signif-
icantly Aﬀect HSV-1 Entry in hMSCs. To determine which
receptor were important for HSV-1 entry into hMSCs,
previously established receptor speciﬁc antibodies were used
[33, 36]. As shown in Figure 5(b), antibody against nectin-
1a ﬀected HSV-1 entry by 20%, while HVEM had no
signiﬁcant eﬀect on HSV-1 entry suggesting that neither
of these receptors plays a critical role in mediating HSV-1
infection of hMSCs.
3.7. Signiﬁcance of HS and 3-OST-3 as the Mediator of HSV-
1 Entry and gD Binding to Cultured hMSCs. Expression of
3-OST-3 raised the possibility that 3-OS HS could be a
mediator of HSV-1 entry into hMSCs. Since cells that use 3-
OSHSasthemajorentryreceptorbecomesigniﬁcantlymore
resistant to HSV-1 upon removal of HS from the surface
[37, 38], we examined the eﬀect of HS-degrading enzyme
heparinase-I (1.5UmL−1) on HSV-1K26GFP binding and
entry into hMSCs. This enzyme is known to cleave oﬀ both
heparin and HS chains containing 1–4 linkages between
glucosamine and O-sulfated iduronic acid residues [42].
As shown in Figure 5(c), heparinase-treated hMSCs (H+)
were resistant to HSV-1 binding (panel B) compared to the
mock-treated cells (H-, panel A). Similar resistance to HSV-
1 KOS gL86 entry was also observed as a result of heparinase
treatment (Figure 5(d)). Next, we tested whether a soluble
recombinant form of HSV-1 gD or gD-Fc [29, 35]w o u l d
bind cultured hMSCs and whether this binding could be
adversely aﬀected by removal of HS from the surface using
cell enzyme-linked immunosorbent assay [26, 28, 33]. Cells
eithertreatedwithheparinasesormock-treatedwereallowed
to bind equal amount of gD, and binding was detected
withaspectrophotometer.Figure 5(e)showsthatgDbinding
to mock-treated hMSCs was not aﬀected; however, the
binding of gD to heparinase-treated hMSCs was reduced
by about 75%. This ﬁnding strongly supports that gD-
bindingreceptorswerespeciﬁcallyremoveduponheparinase
treatment in hMSCs, indicating that HS and 3-OST-3 play
critical roles in mediating HSV-1 entry through gD binding
to cultured hMSCs.
3.8. Requirement of 3-OS HS for HSV-1 Glycoprotein-Induced
Cell-to-Cell Fusion of Cultured hMSCs. To further verify that
3-OS HS is indeed the mediator of the membrane fusion that
occurs during HSV-1 entry into hMSCs, we used a quanti-
tative and eﬃcient cell-to-cell fusion assay [14, 22]. It has
been shown that, similar to the membrane fusion that occurs
during entry, cells expressing HSV-1 glycoproteins gB, gD,
gH, and gL fuse with cells expressing gD receptors [18], and
thus cell-to-cell fusion mimics the minimum requirement
forentry.First,westudiedthesigniﬁcanceofHSinthefusion
of hMSCs with HSV-1 glycoproteins expressing eﬀector
CHO-K1cells.HSdependenceisawaytodeterminewhether
3-OSHSistheprincipalmediatorofmembranefusionsince,
unlike nectin-1 and HVEM, which do not require HS for
membrane fusion, 3-OS HS-mediated cell fusion is highly
dependent on the expression of HS on the cell surface [22].
As expected, fusion of hMSCs with eﬀector cells expressing
the HSV-1 glycoproteins was signiﬁcantly reduced upon
heparinase treatment (Figure 6(a)), and a similar result was
seen with CHO-K1 expressing 3-OST-3 (data not shown),
suggesting that expression of HS and 3-OS HS in hMSCs
arerequiredforeﬀectivefusionwithglycoproteinexpressing-
CHO-K1 cells. In a separate set of experiments, heparinase
treatment also reduced multinucleated giant cell formation
or polykaryons in hMSCs cocultured with eﬀector CHO-K1
cells expressing HSV-1 glycoproteins (Figures 6(b) and 6(c)).
Taken together, our results demonstrate that HS and 3-OS
HS are required for HSV-1 glycoprotein-induced cell to cell
fusion in cultured hMSCs, further implying their signiﬁcant
role in mediating HSV-1 entry and spread into hMSCs.
4. Discussion
HSV-1 infections remain a signiﬁcant problem for allogeneic
stem cell recipients. Understanding viral entry into hMSCs8 Journal of Biomedicine and Biotechnology
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Figure 5: 3-OS HS but not Nectin-1 or HVEM serves as the critical gD receptor in mediating HSV-1 entry into hMSCs. (a) Expression
of HSV-1 glycoprotein D (gD) receptors in hMSCs. RT-PCR analysis of nectin-1, 3-OST-3, and HVEM demonstrated that all 3 genes are
normally expressed by hMSCs. No products were detected in the H2O or RNA lanes in which H2O or the same RNA that was used in
generating cDNA templates was used as PCR template to control for potential genomic DNA contamination. The products were separated
by electrophoresis on an agarose gel. (b) HSV-1 entry into hMSCs was not signiﬁcantly aﬀected by anti-nectin-1 or anti-HVEM antibody
treatment. Cells were preincubated with anti-nectin-1 and anti-HVEM antibodies (1:10 dilution) followed by infection with reporter HSV-
1 (KOS) gL86 virus. β-galactosidase activity was recorded 6h later to determine HSV-1 entry. The experiment was repeated three times
with similar results. (c) Visualization of heparinase treatment on HSV-1 binding into hMSCs. Cultured hMSCs were mock-treated with
PBS (H−) or heparinase I (1.5UmL−1) (H+), followed by exposure to GFP-tagged HSV-1 K26GFP virus at 50pfu/cell for 30min at 4◦C.
Cells were then stained with rhodamine phalloidin that recognizes F-actin (red). Only mock-treated but not heparinase-treated cells showed
HSV-1 GFP binding, which appeared yellow when its green ﬂuorescence overlaps with red ﬂuorescence. Virus attachment was determined
by using Olympus IX50 inverted ﬂuorescence microscope. (d) Eﬀect of heparinase treatment on HSV-1 entry into hMSCs. Cells were treated
with heparinase I (1.5UmL−1) (white bar) or mock-treated with PBS alone (black bar), followed by exposure to HSV-1 KOS gL86 at
50pfu/cell.Viralentrywasquantitated6hrlaterbyONPGassay.Viralentrywasreducedmorethan3foldsincellspretreatedwithheparinase
compared to mock-treated cells (∗∗P<. 01, t test). Data shown are the means of triplicate measures. (e) Eﬀect of heparinase treatment on
HSV-1 gD binding to hMSCs. The cells were either pretreated with a mixture of heparinase-I (treated at 1.5UmL−1; white bar) or mock-
treated (untreated; black bar), followed by exposure to a soluble recombinant form of HSV-1 gD (gD:Fc). Binding of gD:Fc was detected by
using HRP-tagged antibody against IgG:Fc and subsequent HRP enzyme detection. Asterisks indicate signiﬁcant diﬀerence from the control
treatment (∗∗P<. 01, t test). Error bars represent standard deviation (SD).
in a healthy donor or in a recipient host is important for
two reasons. First, productive viral infection into hMSCs
may trigger immune response during or after stem cell
transplant and, second, the infected population of hMSCs
may become large reservoir of virions which may constantly
expand both immune response and the viral transmission
to the localized cells or tissues or may ﬁnd the new host
cells and tissues in the recipient. Therefore, viral receptor on
these cells could determine the type of the infection, nature
of immune response, and viral transmission. We cultured
hMSCs derived from the adipose tissue of healthy donors
to develop an in vitro model for studies of HSV-1 entry
and replication and for identiﬁcation of cellular mediators
of entry. Although all the three HSV-1 gD-receptors (nectin-
1, 3-OST-3 and HVEM) were detected, however, antibodies
against nectin-1 and HVEM failed to block signiﬁcantly
HSV-1 entry (Figures 5(a) and 5(b)). Therefore, our focus
shifted to 3-OS HS as a potential entry receptor. Adding
further strength to this possibility, heparinase enzymes
completely abolished both HSV-1 attachment (Figure 5(c))Journal of Biomedicine and Biotechnology 9
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Figure 6: Eﬀect of heparinase on quantitative HSV-1 glycoprotein-induced fusion with hMSCs. (a) In this experiment, the eﬀector CHO-
K1 cells were transfected with HSV-1 glycoproteins gB, gD, gH, and gL, and T7 RNA polymerase. The target hMSCs were transfected with
plasmids expressing luciferase reporter gene. A luciferase reporter assay was performed 24h after the two cell populations were mixed
together. Cell fusion was measured in relative luciferase units (RLUs). Expression of gD receptors in hMSCs results in the fusion of CHO-K1
cells with HSV-1 glycoprotein expressing cells (black bar), while in a negative control coculture of target cells with eﬀector cells devoid of
all four glycoproteins-encoding genes, no luciferase activity was recorded (white bar). Coculture of heparinase (H+) pretreated-target cells
with eﬀector cells resulted in signiﬁcant decrease in cell fusion (grey bar). (b). The eﬀects of heparinase on multinucleated polykaryocytes
formation were visualized. Multinucleated cells or polykaryocytes were microscopically observed with the hMSC target cells cocultured
with eﬀector CHO-K1 cells expressing HSV-1 glycoproteins (panel (B)) but not with CHO-K1 cells expressing control vector pDream2.1
(panel (A)) or with the pretreatment of target hMSCs with heparinase-I (1.5UmL−1) before mixing with eﬀector cells (panel (C)). Both
type of cells were cocultured and stained with Giemsa at 24h postmixing. Shown are photographs of representative cells (Olympus IX50
inverted microscope) after 24h postmixing. (c) Quantitative determination of the number of fused polykaryocytes formed after coculture
of target hMSCs cocultured with the eﬀector CHO-K1 cells expressing HSV-1 glycoproteins in presence (grey bar) or absence (black bar) of
heparinase. Eﬀector CHO-K1 cells expressing empty vector (pCDNA3.1) cultured with target hMSCs was used as a negative control (white
bar). The data shown are the means of triplicate measures with three independent experiments. Asterisks indicate signiﬁcant diﬀerence from
other treatments (∗∗P<. 01, t test), and error bars represent standard deviation (SD).
and entry into cultured hMSCs (Figure 5(d)). In addition,
the gD binding exhibited sensitivity to enzyme treatment
(Figure 5(e)) and the eﬀect of heparinase to viral spread
during cell to cell fusion assay was also signiﬁcantly inhibited
in cultured hMSCs (Figure 6). Similar eﬀect of heparinase
treatment on HSV-1 entry and fusion has been shown
in primary cultures of corneal ﬁbroblasts obtained from
human eye donors or in the cells exclusively expressing 3-
OST isoforms [28, 29, 33]. Taken together, we speculate one
interesting possibility that although all the three known gD-
receptors are expressed in hMSCs but HSV-1 preferentially
usesHS/3-OS-HStogainentrycouldberelatedfortwomain
reasons. First HS and 3-OS HS being larger in size are widely
distributed and expressed all over the surface of the cells.10 Journal of Biomedicine and Biotechnology
Second they are also easily accessible to HSV-1 unlike nectin-
1 which is localized in celljunctions. This is also possible that
nectin-1 and HVEM receptors are involved in other complex
interactions that do not support HSV-1 entry into hMSCs.
Insummary ,weconcludeHSand3-OSHSplayakeyrole
during HSV-1 infection into hMSCs. The ﬁnding provides
newinformationonsusceptiblenatureofhMSCspopulation
within the host cell and contributes the broader signiﬁcance
of HS and 3-OS HS receptor in HSV-1 infection. Because
HS also play a key role in signaling and immune activation
[43], it is possible that they might play a dual role allowing
both HSV-1 infection and facilitating the inﬂammation to
further damage hMSCs. This unique feature of HS/3-OSH S
in hMSCs can be exploited to develop the agent that blocks
HSV-1 gD interaction with 3-OSH Sr e c e p t o rt os u p p r e s s
both viral entry/spread and immune response. Finally,
hMSCs have potential to diﬀerentiate into many other cell-
types including neurons. Interestingly, HS is known to
mediatetheproliferationanddiﬀerentiationinmesenchymal
stem cells [44]. Therefore it will be interesting to evaluate
the expression pattern of gD-receptors in diﬀerentiated
stem cells including neuronal stem cells where HSV-1 can
easily infect and establish latency. Similarly the strategic
development to isolate population of stem cell lines that does
not support HSV-1 infection may further suppress the HSV-
1-induced morbidity and mortality and bring enhanced
success of stem cell transplantation.
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